Oncocyte Corp share price logo

Oncocyte Corp Share Price

NASDAQ: OCX

$3.17

+0.44

(+16.12%)

as on

Bell Icon

The stock has been delisted from the stock exchange on 17 Jun 2025

Oncocyte Corp Stock Performance

as on June 18, 2025 at 1:29 am IST

  • $3.17
    $3.17
  • 52 Week's Low

    52 Week's High

    $1.92
    $4.75
    downward going graph

    39.37%

    Downside

    49.84%

    Upside

    downward going graph

Oncocyte Corp share price movements today

Previous Close
$2.73
Open
$3.17
Volume
3.5K
Day's Low - High
$3.17 - $3.17
52 Week Low - High
$1.92 - $4.75

Oncocyte Corp Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Oncocyte Corp Stock Fundamentals & Key Indicators

Check Oncocyte Corp market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

Return On Equity TTM

0.00%

Oncocyte Corp stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Oncocyte Corp with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$-NANA0.00%

Analyst Recommendation on Oncocyte Corp Stock

Based on 8 analysts

BUY

62.50%

Buy

37.50%

Hold

0.00%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'BUY' rating for Oncocyte Corp. Average target price of $5.42

Oncocyte Corp Share Price Target

Get share price movements and forecasts by analysts on Oncocyte Corp.

What analysts predicted

41.51%UPSIDE

Target Price

$5.42

Current Price

$3.17

Analyzed by

8 Analysts

Target

$5.42

Oncocyte Corp target price $5.42, a slight upside of 41.51% compared to current price of $3.17. According to 8 analysts rating.

Oncocyte Corp Quarterly Profit & Loss

All numbers in Millions USD

Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Total Revenue
0
0
0
0
0
0
0
0
1
2
Gross Profit
0
0
0
0
0
0
0
0
0
1
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-44
-45
-8
-6
-15
-9
-4
-13
-33
-6
Net Profit Margin
-16415.33%
-15264.31%
-1799.78%
-1512.59%
-5092.99%
-5186.93%
-4355.77%
-11733.04%
-2255.11%
-312.02%

Oncocyte Corp Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
0
1
7
0
1
1
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-8
-11
-19
-15
-22
-29
-64
-73
-27
-60
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-139556.25%
-2461.51%
-829.52%
-7665.97%
-1848.37%
-3225.04%

Global Institutional Holdings in Oncocyte Corp

Funds
Holdings
BROADWOOD CAPITAL Inc
39.9%
Awm Investment Company Inc
9.87%
PURA VIDA INVESTMENTS, LLC
3.31%
Vanguard Group Inc
0.93%
Geode Capital Management, LLC
0.56%

About Oncocyte Corp

Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
OrganisationOncocyte Corp
E-voting on sharesClick here to vote

FAQs

What is Oncocyte Corp share price today?

Oncocyte Corp share price today is $3.17 as on at the close of the market. Oncocyte Corp share today touched a day high of $3.17 and a low of $3.17.

What is the 52 week high and 52 week low for Oncocyte Corp share?

Oncocyte Corp share touched a 52 week high of $4.75 on and a 52 week low of $1.92 on . Oncocyte Corp stock price today i.e. is closed at $3.17,which is 33.26% down from its 52 week high and 64.93% up from its 52 week low.

How to invest in Oncocyte Corp Stock (OCX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Oncocyte Corp on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Oncocyte Corp Shares that will get you 0.4732 shares as per Oncocyte Corp share price of $3.17 per share as on June 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Oncocyte Corp Stock (OCX) from India?

Indian investors can start investing in Oncocyte Corp (OCX) shares with as little as ₹88.114 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Oncocyte Corp stock (as per the Rupee-Dollar exchange rate as on ). Based on Oncocyte Corp share’s latest price of $3.17 as on June 18, 2025 at 1:29 am IST, you will get 3.1546 shares of Oncocyte Corp. Learn more about fractional shares .